IMO Leo's sole focus is building and maximizing shareholder wealth. He has been and will do whatever means is necessary and available. Leo has had a difficult challenge to balance science advancement versus stock dilution. The criminal attacks against IPIX has forced Leo to use dilutive MFO financing as very expensive capital. IMO Leo’s only mistake was not being aware of this criminal attempt back when SP was over $2 and hoarding a couple years-worth of cash for future trials. Hind sight is 20/20. With that said, I personally believe having Brilacidin advanced to this point with only a 294M OS is testament to an excellent job by Leo in the past couple of years. Also note that IPIX has spent $100M in its entire existence to bring both Brilacidin and Kevetrin to their current science advancement and positioning.
I do not believe Leo’s mission is to “reform the BP cabal”. Leo’s energy is focused on getting Brilacidin to market, period. Remember that Leo bought the rights to Brilacidin for $5M in stock from a bankrupt company who created the drug using super-computing, AI development with the idea to advance it through trials. This $5M investment could very well turn out to produce billions of dollars of revenue annually. Prior to February IPIX’s primary goal was to get BP partnerships for B-OM and B-IBD Oral. The IBD market is a $48B market and Brilacidin could capture many of those billions in revenue. Take a WORSE CASE scenario of only getting $4B of that $48B market with a small 10% royalty. That would equate to $400M in annual revenue, most of which would be earnings with a current $5M-$12M expense rate. If we take grotty’s 400M full dilution number (It could be much lower if IPIX secures grant money in the coming weeks) that would equate to around $1 per share in earnings. A lowball valuation using a PE ratio is 20-30 for growth companies. Biotech companies usually are not valued using a PE ratio as most biotech companies are not profitable. This would conservatively make IPIX value of $20 to $30 per share once Brilacidin was approved and on the market producing revenues which in turn produce royalty revenue. I personally was more than happy with the risk/reward owning IPIX based strictly on B-IBD Oral only. B-OM and other Brilacidin revenue as well as any future Kevetrin revenue would be additional value.
In 2020 the COVID-19 (CV19) pandemic hit and now Brilacidin has been progressively tested as a treatment. Successful testing proving the attributes as an anti-viral, anti-inflammatory and antimicrobial are positioning Brilacidin as potentially the optimal treatment to combat CV19. If IPIX gets a government grant and proceeds with successful CV19 trials than all SP evaluations above can be thrown out the window. Government grant money would likely diminish the need for a CV19 partnership. That would mean that instead of royalty revenue (minority of total revenue) for CV19 that IPIX would be attaining the vast majority of revenue and that in turn will be mostly pure profit in the form of earnings. Additionally, Brilacidin would be quickly advanced through human trials and be FDA approved. This in turn will make it much more streamlined to get B-OM and B-IBD Oral through phase 3 trials. The further the science is advanced the less risk and funding that BP takes on and thus the royalty agreements become much more lucrative for the biotech supplying the drug to BP. This would strengthen Leo’s hand for negotiating much more lucrative B-OM and B-IBD Oral royalty partnerships than in the above example.
The milestones of attaining grant money, successful CV19 human trials, eventual approval of Brilacidin, and finally recurring revenue will each individually create new investor demand which will have a positive impact on IPIX SP. Think about the investor demand that will take place if Brilacidin becomes the CV19 treatment of choice! There are a lot of “ifs” to take us from where we are today but the upside is enormous. IMO because of this enormous upside it would not be wise for IPIX to sell or license out Brilacidin in its entirety AT THIS TIME. Once revenues flow from multiple instances the valuation of Brilacidin will be based on concrete numbers and not on a lot of ifs and maybes and would bring in a much more lucrative valuation.
Note that the criminal control of IPIX SP will not immediately go away but rather will gradually loosen as milestones are met. IMO SP will not shoot straight up but will zig-zag upwards as milestones are achieved. The criminals are good at what they do and they will continue to spoof volume and compress SP. Paid soft bashers will continue to try to scare investors that the market opportunity has past, future drug trials may fail or that the current artificially compressed SP is the foundation that future growth should be calculated from. The criminals will look at fake volume and incorrectly blame the compressed SP on MFO selling.
The criminals will try to project low valuations of $2 or $3 as a great exit strategy point. Even once IPIX SP spikes up in dollars the criminals cannot cover their naked position until real investors sell them real shares. The unwinding of the criminal NSS position (squeeze) IMO will not be in a meaningful way until SP is between $5 and $20. Some will incorrectly claim victory over the criminals in the initial spike up or 2. New investor demand and the eventual criminal unwinding will significantly increase IPIX SP. Each individual needs to make their own decision at which price point they start any exit strategy but IMO the longer investors hold, the higher SP will be.
I do not believe Leo’s mission is to “reform the BP cabal”. Leo’s energy is focused on getting Brilacidin to market, period. Remember that Leo bought the rights to Brilacidin for $5M in stock from a bankrupt company who created the drug using super-computing, AI development with the idea to advance it through trials. This $5M investment could very well turn out to produce billions of dollars of revenue annually. Prior to February IPIX’s primary goal was to get BP partnerships for B-OM and B-IBD Oral. The IBD market is a $48B market and Brilacidin could capture many of those billions in revenue. Take a WORSE CASE scenario of only getting $4B of that $48B market with a small 10% royalty. That would equate to $400M in annual revenue, most of which would be earnings with a current $5M-$12M expense rate. If we take grotty’s 400M full dilution number (It could be much lower if IPIX secures grant money in the coming weeks) that would equate to around $1 per share in earnings. A lowball valuation using a PE ratio is 20-30 for growth companies. Biotech companies usually are not valued using a PE ratio as most biotech companies are not profitable. This would conservatively make IPIX value of $20 to $30 per share once Brilacidin was approved and on the market producing revenues which in turn produce royalty revenue. I personally was more than happy with the risk/reward owning IPIX based strictly on B-IBD Oral only. B-OM and other Brilacidin revenue as well as any future Kevetrin revenue would be additional value.
In 2020 the COVID-19 (CV19) pandemic hit and now Brilacidin has been progressively tested as a treatment. Successful testing proving the attributes as an anti-viral, anti-inflammatory and antimicrobial are positioning Brilacidin as potentially the optimal treatment to combat CV19. If IPIX gets a government grant and proceeds with successful CV19 trials than all SP evaluations above can be thrown out the window. Government grant money would likely diminish the need for a CV19 partnership. That would mean that instead of royalty revenue (minority of total revenue) for CV19 that IPIX would be attaining the vast majority of revenue and that in turn will be mostly pure profit in the form of earnings. Additionally, Brilacidin would be quickly advanced through human trials and be FDA approved. This in turn will make it much more streamlined to get B-OM and B-IBD Oral through phase 3 trials. The further the science is advanced the less risk and funding that BP takes on and thus the royalty agreements become much more lucrative for the biotech supplying the drug to BP. This would strengthen Leo’s hand for negotiating much more lucrative B-OM and B-IBD Oral royalty partnerships than in the above example.
The milestones of attaining grant money, successful CV19 human trials, eventual approval of Brilacidin, and finally recurring revenue will each individually create new investor demand which will have a positive impact on IPIX SP. Think about the investor demand that will take place if Brilacidin becomes the CV19 treatment of choice! There are a lot of “ifs” to take us from where we are today but the upside is enormous. IMO because of this enormous upside it would not be wise for IPIX to sell or license out Brilacidin in its entirety AT THIS TIME. Once revenues flow from multiple instances the valuation of Brilacidin will be based on concrete numbers and not on a lot of ifs and maybes and would bring in a much more lucrative valuation.
Note that the criminal control of IPIX SP will not immediately go away but rather will gradually loosen as milestones are met. IMO SP will not shoot straight up but will zig-zag upwards as milestones are achieved. The criminals are good at what they do and they will continue to spoof volume and compress SP. Paid soft bashers will continue to try to scare investors that the market opportunity has past, future drug trials may fail or that the current artificially compressed SP is the foundation that future growth should be calculated from. The criminals will look at fake volume and incorrectly blame the compressed SP on MFO selling.
The criminals will try to project low valuations of $2 or $3 as a great exit strategy point. Even once IPIX SP spikes up in dollars the criminals cannot cover their naked position until real investors sell them real shares. The unwinding of the criminal NSS position (squeeze) IMO will not be in a meaningful way until SP is between $5 and $20. Some will incorrectly claim victory over the criminals in the initial spike up or 2. New investor demand and the eventual criminal unwinding will significantly increase IPIX SP. Each individual needs to make their own decision at which price point they start any exit strategy but IMO the longer investors hold, the higher SP will be.
25
2
